Expression of HAb18G/CD147 and its localization correlate with the progression and poor prognosis of non-small cell lung cancer

Abstract This study was designed to investigate the association of HAb18G/CD147 expression and localization with clinicopathological parameters and prognosis in NSCLC. Two hundred and eight (208) specimens of surgically resected NSCLC were stained by immunohistochemistry utilizing mouse anti-human HAb18G/CD147 monoclonal antibody. High levels of HAb18G/CD147 expression were associated with male gender, smoking history, tumor position, distant metastasis status, and clinical stage ( p p p p p  = 0.017), distant metastasis status (HR = 3.789, 95%CI 2.196–6.539, p  = 0.000), expression (HR = 6.632, 95%CI 2.457–17.904, p  = 0.000), and localization (HR = 0.520, 95%CI 0.341–0.794, p  = 0.002) were good or excellent independent predictors of patient survival. HAb18G/CD147 is a biomarker characterizing progression and survival of NSCLC. More importantly, its cellular localizations should be considered in the analysis of clinicopathological characteristics and prognostic factors in NSCLC.